RNTX Key Statistics, Chart & Performance
The current stock price of RNTX is 1.48 USD. In the past month the price increased by 2.78%.
RNTX Latest News, Press Relases and Analysis
RNTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About RNTX
Company Profile
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 11 full-time employees. The company went IPO on 2017-06-29. The firm's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
Company Info
REIN THERAPEUTICS INC
12407 N. Mopac Expy., Suite 250 #390
Austin TEXAS US
Employees: 11
Phone: 17378021989
REIN THERAPEUTICS INC / RNTX FAQ
What does RNTX do?
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 11 full-time employees. The company went IPO on 2017-06-29. The firm's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
What is the current price of RNTX stock?
The current stock price of RNTX is 1.48 USD. The price increased by 7.25% in the last trading session.
Does REIN THERAPEUTICS INC pay dividends?
RNTX does not pay a dividend.
What is the ChartMill rating of REIN THERAPEUTICS INC stock?
RNTX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for REIN THERAPEUTICS INC?
REIN THERAPEUTICS INC (RNTX) operates in the Health Care sector and the Biotechnology industry.
RNTX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to RNTX.
RNTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RNTX. The financial health of RNTX is average, but there are quite some concerns on its profitability.
RNTX Financial Highlights
Over the last trailing twelve months RNTX reported a non-GAAP Earnings per Share(EPS) of -2.94. The EPS increased by 5.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -109.64% | ||
| ROE | -127.48% | ||
| Debt/Equity | 0 |
RNTX Forecast & Estimates
8 analysts have analysed RNTX and the average price target is 8.16 USD. This implies a price increase of 451.35% is expected in the next year compared to the current price of 1.48.